Artificial Insemination Market Size, Share & Trends Analysis Report By Type (Intrauterine, Intracervical, Intravaginal, Intratubal), By Source Outlook, By End Use (AIH-Husband And AID-Donor), By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Artemisinin Combination Therapy Market Growth & Trends
The global artemisinin combination therapy market size is expected to reach USD 1,018.7 million by 2030, registering a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising adoption rate of ACTs coupled with growing government initiatives to combat the malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market.
Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries.
Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market.
WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies because parasites have developed resistance to these medicines.
Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend.
Artemisinin Combination Therapy Market Report Highlights
Artemisinin Combination Therapy Market Growth & Trends
The global artemisinin combination therapy market size is expected to reach USD 1,018.7 million by 2030, registering a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising adoption rate of ACTs coupled with growing government initiatives to combat the malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market.
Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries.
Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market.
WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies because parasites have developed resistance to these medicines.
Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend.
Artemisinin Combination Therapy Market Report Highlights
- Artemether+Lumefantrine dominated the market and accounted for a share of 37.1% in 2023. The rising demand for Artemether+Lumefantrine can be attributed to its superior effectiveness and safety in treating uncomplicated malaria.
- North America artemisinin combination therapy market held the largest market revenue share of 37.7% in 2023. The increasing demand is primarily due to the rising number of imported malaria cases and the need for effective treatment options.
- Asia Pacific artemisinin combination therapy market is anticipated to grow at the fastest CAGR over the forecast period. The demand for artemisinin combination therapy (ACT) in the.
- Asia-Pacific region is increasing due to the resurgence of malaria and the growing resistance to traditional antimalarial drugs.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. ARTIFICIAL INSEMINATION MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Artificial Insemination Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. ARTIFICIAL INSEMINATION MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Artificial Insemination Market: Type Movement Analysis, 2023 & 2030 (USD Million)
4.3. Intrauterine Insemination
4.3.1. Intrauterine Insemination Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Intracervical Insemination
4.4.1. Intracervical Insemination Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Intravaginal Insemination
4.5.1. Intravaginal Insemination Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Intratubal Insemination
4.6.1. Intratubal Insemination Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. ARTIFICIAL INSEMINATION MARKET: SOURCE ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Artificial Insemination Market: Source Movement Analysis, 2023 & 2030 (USD Million)
5.3. AIH-Husband
5.3.1. AIH-Husband Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. AID-Donor
5.4.1. AID-Donor Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. ARTIFICIAL INSEMINATION MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Artificial Insemination Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
6.3. Fertility Clinics & Other Facilities
6.3.1. Fertility clinics & other facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Home
6.4.1. Home Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. ARTIFICIAL INSEMINATION MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Artificial Insemination Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
7.2.1. North America Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Vitrolife
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Genea Pty Limited
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Rinovum Women’s Health, LLC
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Pride Angel
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. HI-TECH SOLUTIONS
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. FUJIFILM Irvine Scientific
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Kitazato Corporation
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Rocket Medical plc
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Conceivex, Inc.
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. ARTIFICIAL INSEMINATION MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Artificial Insemination Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. ARTIFICIAL INSEMINATION MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Artificial Insemination Market: Type Movement Analysis, 2023 & 2030 (USD Million)
4.3. Intrauterine Insemination
4.3.1. Intrauterine Insemination Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Intracervical Insemination
4.4.1. Intracervical Insemination Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Intravaginal Insemination
4.5.1. Intravaginal Insemination Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Intratubal Insemination
4.6.1. Intratubal Insemination Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. ARTIFICIAL INSEMINATION MARKET: SOURCE ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Artificial Insemination Market: Source Movement Analysis, 2023 & 2030 (USD Million)
5.3. AIH-Husband
5.3.1. AIH-Husband Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. AID-Donor
5.4.1. AID-Donor Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. ARTIFICIAL INSEMINATION MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Artificial Insemination Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
6.3. Fertility Clinics & Other Facilities
6.3.1. Fertility clinics & other facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Home
6.4.1. Home Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. ARTIFICIAL INSEMINATION MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Artificial Insemination Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
7.2.1. North America Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Artificial Insemination Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Vitrolife
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Genea Pty Limited
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Rinovum Women’s Health, LLC
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Pride Angel
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. HI-TECH SOLUTIONS
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. FUJIFILM Irvine Scientific
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Kitazato Corporation
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Rocket Medical plc
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Conceivex, Inc.
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
